KRYS
Price
$154.05
Change
-$0.33 (-0.21%)
Updated
Sep 17 closing price
Capitalization
4.47B
53 days until earnings call
NTLA
Price
$12.41
Change
+$0.14 (+1.14%)
Updated
Sep 17 closing price
Capitalization
1.32B
49 days until earnings call
Interact to see
Advertisement

KRYS vs NTLA

Header iconKRYS vs NTLA Comparison
Open Charts KRYS vs NTLABanner chart's image
Krystal Biotech
Price$154.05
Change-$0.33 (-0.21%)
Volume$280.63K
Capitalization4.47B
Intellia Therapeutics
Price$12.41
Change+$0.14 (+1.14%)
Volume$6.88M
Capitalization1.32B
KRYS vs NTLA Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. NTLA commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (KRYS: $154.13 vs. NTLA: $12.41)
Brand notoriety: KRYS and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 80% vs. NTLA: 148%
Market capitalization -- KRYS: $4.47B vs. NTLA: $1.32B
KRYS [@Biotechnology] is valued at $4.47B. NTLA’s [@Biotechnology] market capitalization is $1.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than KRYS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 7 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 7 bullish, 2 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than NTLA.

Price Growth

KRYS (@Biotechnology) experienced а +12.12% price change this week, while NTLA (@Biotechnology) price change was +9.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.47B) has a higher market cap than NTLA($1.32B). NTLA YTD gains are higher at: 6.432 vs. KRYS (-1.618). KRYS has higher annual earnings (EBITDA): 158M vs. NTLA (-501.87M). KRYS has more cash in the bank: 682M vs. NTLA (460M). KRYS has less debt than NTLA: KRYS (9.68M) vs NTLA (103M). KRYS has higher revenues than NTLA: KRYS (359M) vs NTLA (52.9M).
KRYSNTLAKRYS / NTLA
Capitalization4.47B1.32B339%
EBITDA158M-501.87M-31%
Gain YTD-1.6186.432-25%
P/E Ratio31.33N/A-
Revenue359M52.9M679%
Total Cash682M460M148%
Total Debt9.68M103M9%
FUNDAMENTALS RATINGS
KRYS vs NTLA: Fundamental Ratings
KRYS
NTLA
OUTLOOK RATING
1..100
6614
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
39100
SMR RATING
1..100
5398
PRICE GROWTH RATING
1..100
5945
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for KRYS (65) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTLA (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than NTLA’s over the last 12 months.

KRYS's SMR Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTLA (98) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than NTLA’s over the last 12 months.

NTLA's Price Growth Rating (45) in the Biotechnology industry is in the same range as KRYS (59) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as NTLA (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSNTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 29 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTXAX50.73N/A
N/A
FullerThaler Behavioral Sm-Cp Gr A
GRINX24.10N/A
N/A
Victory Diversified Stock R
SNPTX20.81N/A
N/A
DWS Equity Sector Strategy Institutional
KLGIX58.82-0.24
-0.41%
NYLI WMC Growth Class I
FNEEX74.24-0.52
-0.70%
American Funds New Economy 529-F-2

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.17%
XNCR - KRYS
52%
Loosely correlated
+7.31%
VRDN - KRYS
50%
Loosely correlated
-0.21%
CRNX - KRYS
49%
Loosely correlated
+0.29%
ACLX - KRYS
49%
Loosely correlated
-1.20%
CGON - KRYS
48%
Loosely correlated
+5.48%
More